Roles of endothelial nitric oxide synthase (eNOS) and mitochondrial permeability transition pore (MPTP) in epoxyeicosatrienoic acid (EET)-induced cardioprotection against infarction in intact rat hearts

Journal of Molecular and Cellular Cardiology

Volumn 59, Issue , 2013, Pages 20-29

  Gross, Garrett J ^a   Hsu, Anna ^a   Pfeiffer, Adam W ^a   Nithipatikom, Kasem ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Endothelial nitric oxide synthase (eNOS); Epoxyeicosatrienoic acids (EETs); Mitochondrial permeability transition pore (MPTP); Myocardial ischemia reperfusion injury; Nitric oxide (NO)

Indexed keywords

11,12EPOXYICOSATRIENOIC ACID; 14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; CYCLOSPORINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPOXYICOSATRIENOIC ACID; NITRIC OXIDE; UNCLASSIFIED DRUG; 14,15 EICOSA 5 ENOIC ACID; 14,15 EPOXY 5,8,11 EICOSATRIENOIC ACID; 14,15-EICOSA-5-ENOIC ACID; 14,15-EPOXY-5,8,11-EICOSATRIENOIC ACID; CARRIER PROTEIN; DIHOMO GAMMA LINOLENIC ACID; DRUG DERIVATIVE; IMINE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; N ((3 (AMINOMETHYL)PHENYL)METHYL)ETHANIMIDAMIDE; N-((3-(AMINOMETHYL)PHENYL)METHYL)ETHANIMIDAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; H9C2(2-1) CELL LINE; HEART HEMODYNAMICS; HEART INFARCTION; HEART INFARCTION SIZE; HEART PROTECTION; IN VIVO STUDY; MALE; MITOCHONDRIAL PERMEABILITY; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HEART; HEMODYNAMICS; METABOLISM; PHYSIOLOGY; REPERFUSION INJURY; SPRAGUE DAWLEY RAT;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; CELL LINE; HEART; HEMODYNAMICS; IMINES; MALE; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MYOCARDIAL INFARCTION; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY;

EID: 84874932812     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2013.02.003     Document Type: Article

References (60)

1. Gross, G.J., Hsu, A., Falck, J.R., Nithipatikom, K., Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts. J Mol Cell Cardiol 42:3 (Mar 2007), 687–691.
2. Nithipatikom, K., Moore, J.M., Isbell, M.A., Falck, J.R., Gross, G.J., Epoxyeicosatrienoic acids in cardioprotection: ischemic versus reperfusion injury. Am J Physiol Heart Circ Physiol 291:2 (Aug 2006), H537–H542.
3. Seubert, J.M., Sinal, C.J., Graves, J., DeGraff, L.M., Bradbury, J.A., Lee, C.R., et al. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res 99:4 (Aug 18 2006), 442–450.
4. Seubert, J., Yang, B., Bradbury, J.A., Graves, J., Degraff, L.M., Gabel, S., et al. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K + channels and p42/p44 MAPK pathway. Circ Res 95:5 (Sep 3 2004), 506–514.
5. Motoki, A., Merkel, M.J., Packwood, W.H., Cao, Z., Liu, L., Iliff, J., et al. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo. Am J Physiol Heart Circ Physiol 295:5 (Nov 2008), H2128–H2134.
6. Gross, G.J., Gauthier, K.M., Moore, J., Falck, J.R., Hammock, B.D., Campbell, W.B., et al. Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. Am J Physiol Heart Circ Physiol 294:6 (Jun 2008), H2838–H2844.
7. Yang, W., Tuniki, V.R., Anjaiah, S., Falck, J.R., Hillard, C.J., Campbell, W.B., Characterization of epoxyeicosatrienoic acid binding site in U937 membranes using a novel radiolabeled agonist, 20-125i-14,15-epoxyeicosa-8(Z)-enoic acid. J Pharmacol Exp Ther 324:3 (Mar 2008), 1019–1027.
8. Behm, D.J., Ogbonna, A., Wu, C., Burns-Kurtis, C.L., Douglas, S.A., Epoxyeicosatrienoic acids function as selective, endogenous antagonists of native thromboxane receptors: identification of a novel mechanism of vasodilation. J Pharmacol Exp Ther 328:1 (Jan 2009), 231–239.
9. Senouvo, F.Y., Tabet, Y., Morin, C., Albadine, R., Sirois, C., Rousseau, E., Improved bioavailability of epoxyeicosatrienoic acids reduces TP-receptor agonist-induced tension in human bronchi. Am J Physiol Lung Cell Mol Physiol 301:5 (Nov 2011), L675–L682.
10. Yang, C., Kwan, Y.W., Au, A.L., Poon, C.C., Zhang, Q., Chan, S.W., et al. 14,15-Epoxyeicosatrienoic acid induces vasorelaxation through the prostaglandin EP(2) receptors in rat mesenteric artery. Prostaglandins Other Lipid Mediat, Jun 30 2010.
11. Pozzi, A., Ibanez, M.R., Gatica, A.E., Yang, S., Wei, S., Mei, S., et al. Peroxisomal proliferator-activated receptor-alpha-dependent inhibition of endothelial cell proliferation and tumorigenesis. J Biol Chem 282:24 (Jun 15 2007), 17685–17695.
12. Ng, V.Y., Huang, Y., Reddy, L.M., Falck, J.R., Lin, E.T., Kroetz, D.L., Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha. Drug Metab Dispos 35:7 (Jul 2007), 1126–1134.
13. Wang, D., Hirase, T., Nitto, T., Soma, M., Node, K., Eicosapentaenoic acid increases cytochrome P-450 2J2 gene expression and epoxyeicosatrienoic acid production via peroxisome proliferator-activated receptor gamma in endothelial cells. J Cardiol 54:3 (Dec 2009), 368–374.
14. Xu, D.Y., Davis, B.B., Wang, Z.H., Zhao, S.P., Wasti, B., Liu, Z.L., et al. A potent soluble epoxide hydrolase inhibitor, t-AUCB, acts through PPARgamma to modulate the function of endothelial progenitor cells from patients with acute myocardial infarction. Int J Cardiol, Apr 21 2012.
15. Bulhak, A.A., Sjoquist, P.O., Xu, C.B., Edvinsson, L., Pernow, J., Protection against myocardial ischaemia/reperfusion injury by PPAR-alpha activation is related to production of nitric oxide and endothelin-1. Basic Res Cardiol 101:3 (May 2006), 244–252.
16. Gonon, A.T., Bulhak, A., Labruto, F., Sjoquist, P.O., Pernow, J., Cardioprotection mediated by rosiglitazone, a peroxisome proliferator-activated receptor gamma ligand, in relation to nitric oxide. Basic Res Cardiol 102:1 (Jan 2007), 80–89.
17. Seubert, J.M., Zeldin, D.C., Nithipatikom, K., Gross, G.J., Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat 82:1–4 (Jan 2007), 50–59.
18. Batchu, S.N., Chaudhary, K.R., El-Sikhry, H., Yang, W., Light, P.E., Oudit, G.Y., et al. Role of PI3Kalpha and sarcolemmal ATP-sensitive potassium channels in epoxyeicosatrienoic acid mediated cardioprotection. J Mol Cell Cardiol 53:1 (Jul 2012), 43–52.
19. Sato, M., Yokoyama, U., Fujita, T., Okumura, S., Ishikawa, Y., The roles of cytochrome p450 in ischemic heart disease. Curr Drug Metab 12:6 (Jul 2011), 526–532.
20. Katragadda, D., Batchu, S.N., Cho, W.J., Chaudhary, K.R., Falck, J.R., Seubert, J.M., Epoxyeicosatrienoic acids limit damage to mitochondrial function following stress in cardiac cells. J Mol Cell Cardiol 46:6 (Jun 2009), 867–875.
21. Hataishi, R., Rodrigues, A.C., Neilan, T.G., Morgan, J.G., Buys, E., Shiva, S., et al. Inhaled nitric oxide decreases infarction size and improves left ventricular function in a murine model of myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 291:1 (Jul 2006), H379–H384.
22. Nagasaka, Y., Fernandez, B.O., Garcia-Saura, M.F., Petersen, B., Ichinose, F., Bloch, K.D., et al. Brief periods of nitric oxide inhalation protect against myocardial ischemia-reperfusion injury. Anesthesiology 109:4 (Oct 2008), 675–682.
23. Liu, X., Huang, Y., Pokreisz, P., Vermeersch, P., Marsboom, G., Swinnen, M., et al. Nitric oxide inhalation improves microvascular flow and decreases infarction size after myocardial ischemia and reperfusion. J Am Coll Cardiol 50:8 (Aug 21 2007), 808–817.
24. Rossoni, G., Manfredi, B., De Gennaro, Colonna V., Brini, A.T., Polvani, G., Clement, M.G., et al. Nitric oxide and prostacyclin pathways: an integrated mechanism that limits myocardial infarction progression in anaesthetized rats. Pharmacol Res 53:4 (Apr 2006), 359–366.
25. Frantz, S., Adamek, A., Fraccarollo, D., Tillmanns, J., Widder, J.D., Dienesch, C., et al. The eNOS enhancer AVE 9488: a novel cardioprotectant against ischemia reperfusion injury. Basic Res Cardiol 104:6 (Nov 2009), 773–779.
26. Lv, L., Jiang, S.S., Xu, J., Gong, J.B., Cheng, Y., Protective effect of ligustrazine against myocardial ischaemia reperfusion in rats: the role of endothelial nitric oxide synthase. Clin Exp Pharmacol Physiol 39:1 (Jan 2012), 20–27.
27. Li, D.Y., Tao, L., Liu, H., Christopher, T.A., Lopez, B.L., Ma, X.L., Role of ERK1/2 in the anti-apoptotic and cardioprotective effects of nitric oxide after myocardial ischemia and reperfusion. Apoptosis 11:6 (Jun 2006), 923–930.
28. Jiang, J.G., Chen, R.J., Xiao, B., Yang, S., Wang, J.N., Wang, Y., et al. Regulation of endothelial nitric-oxide synthase activity through phosphorylation in response to epoxyeicosatrienoic acids. Prostaglandins Other Lipid Mediat 82:1–4 (Jan 2007), 162–174.
29. Wang, H., Lin, L., Jiang, J., Wang, Y., Lu, Z.Y., Bradbury, J.A., et al. Up-regulation of endothelial nitric-oxide synthase by endothelium-derived hyperpolarizing factor involves mitogen-activated protein kinase and protein kinase C signaling pathways. J Pharmacol Exp Ther 307:2 (Nov 2003), 753–764.
30. Chen, R., Jiang, J., Xiao, X., Wang, D., Effects of epoxyeicosatrienoic acids on levels of eNOS phosphorylation and relevant signaling transduction pathways involved. Sci China C Life Sci 48:5 (Oct 2005), 495–505.
31. Braunwald, E., Kloner, R.A., Myocardial reperfusion: a double-edged sword?. J Clin Invest 76:5 (Nov 1985), 1713–1719.
32. Buckberg, G.D., When is cardiac muscle damaged irreversibly?. J Thorac Cardiovasc Surg 92:3 Pt 2 (Sep 1986), 483–487.
33. Vinten-Johansen, J., Johnston, W.E., Mills, S.A., Faust, K.B., Geisinger, K.R., DeMasi, R.J., et al. Reperfusion injury after temporary coronary occlusion. J Thorac Cardiovasc Surg 95:6 (Jun 1988), 960–968.
34. Weiss, J.N., Korge, P., Honda, H.M., Ping, P., Role of the mitochondrial permeability transition in myocardial disease. Circ Res 93:4 (Aug 22 2003), 292–301.
35. Halestrap, A.P., Clarke, S.J., Javadov, S.A., Mitochondrial permeability transition pore opening during myocardial reperfusion—a target for cardioprotection. Cardiovasc Res 61:3 (Feb 15 2004), 372–385.
36. Halestrap, A.P., Kerr, P.M., Javadov, S., Woodfield, K.Y., Elucidating the molecular mechanism of the permeability transition pore and its role in reperfusion injury of the heart. Biochim Biophys Acta 1366:1–2 (Aug 10 1998), 79–94.
37. Hausenloy, D.J., Yellon, D.M., The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol 35:4 (Apr 2003), 339–341.
38. Di Lisa, F., Canton, M., Menabo, R., Dodoni, G., Bernardi, P., Mitochondria and reperfusion injury. The role of permeability transition. Basic Res Cardiol 98:4 (Jul 2003), 235–241.
39. Hausenloy, D.J., Duchen, M.R., Yellon, D.M., Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res 60:3 (Dec 1 2003), 617–625.
40. Davidson, S.M., Hausenloy, D., Duchen, M.R., Yellon, D.M., Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J Biochem Cell Biol 38:3 (Mar 2006), 414–419.
41. Gauthier, K.M., Deeter, C., Krishna, U.M., Reddy, Y.K., Bondlela, M., Falck, J.R., et al. 14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res 90:9 (May 17 2002), 1028–1036.
42. Nithipatikom, K., Gross, E.R., Endsley, M.P., Moore, J.M., Isbell, M.A., Falck, J.R., et al. Inhibition of cytochrome P450omega-hydroxylase: a novel endogenous cardioprotective pathway. Circ Res 95:8 (Oct 15 2004), e65–e71.
43. Yang, S., Lin, L., Chen, J.X., Lee, C.R., Seubert, J.M., Wang, Y., et al. Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-alpha via MAPK and PI3K/Akt signaling pathways. Am J Physiol Heart Circ Physiol 293:1 (Jul 2007), H142–H151.
44. Jones, S.P., Greer, J.J., Kakkar, A.K., Ware, P.D., Turnage, R.H., Hicks, M., et al. Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 286:1 (Jan 2004), H276–H282.
45. Talukder, M.A., Yang, F., Shimokawa, H., Zweier, J.L., eNOS is required for acute in vivo ischemic preconditioning of the heart: effects of ischemic duration and sex. Am J Physiol Heart Circ Physiol 299:2 (Aug 2010), H437–H445.
46. Xuan, Y.T., Guo, Y., Zhu, Y., Wang, O.L., Rokosh, G., Bolli, R., Endothelial nitric oxide synthase plays an obligatory role in the late phase of ischemic preconditioning by activating the protein kinase C epsilon p44/42 mitogen-activated protein kinase pSer-signal transducers and activators of transcription1/3 pathway. Circulation 116:5 (Jul 31 2007), 535–544.
47. Gross, G.J., Gauthier, K.M., Moore, J., Campbell, W.B., Falck, J.R., Nithipatikom, K., Evidence for role of epoxyeicosatrienoic acids in mediating ischemic preconditioning and postconditioning in dog. Am J Physiol Heart Circ Physiol 297:1 (Jul 2009), H47–H52.
48. Barua, A., Standen, N.B., Galinanes, M., Dual role of nNOS in ischemic injury and preconditioning. BMC Physiol, 10, 2010, 15.
49. Lu, X.M., Zhang, G.X., Yu, Y.Q., Kimura, S., Nishiyama, A., Matsuyoshi, H., et al. The opposite roles of nNOS in cardiac ischemia-reperfusion-induced injury and in ischemia preconditioning-induced cardioprotection in mice. J Physiol Sci 59:4 (Jul 2009), 253–262.
50. Wang, Y., Kodani, E., Wang, J., Zhang, S.X., Takano, H., Tang, X.L., et al. Cardioprotection during the final stage of the late phase of ischemic preconditioning is mediated by neuronal NO synthase in concert with cyclooxygenase-2. Circ Res 95:1 (Jul 9 2004), 84–91.
51. Guo, Y., Jones, W.K., Xuan, Y.T., Tang, X.L., Bao, W., Wu, W.J., et al. The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci U S A 96:20 (Sep 28 1999), 11507–11512.
52. Wang, Y., Guo, Y., Zhang, S.X., Wu, W.J., Wang, J., Bao, W., et al. Ischemic preconditioning upregulates inducible nitric oxide synthase in cardiac myocyte. J Mol Cell Cardiol 34:1 (Jan 2002), 5–15.
53. Jones, S.P., Bolli, R., The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol 40:1 (Jan 2006), 16–23.
54. Wakeno-Takahashi, M., Otani, H., Nakao, S., Imamura, H., Shingu, K., Isoflurane induces second window of preconditioning through upregulation of inducible nitric oxide synthase in rat heart. Am J Physiol Heart Circ Physiol 289:6 (Dec 2005), H2585–H2591.
55. West, M.B., Rokosh, G., Obal, D., Velayutham, M., Xuan, Y.T., Hill, B.G., et al. Cardiac myocyte-specific expression of inducible nitric oxide synthase protects against ischemia/reperfusion injury by preventing mitochondrial permeability transition. Circulation 118:19 (Nov 4 2008), 1970–1978.
56. Ljubkovic, M., Shi, Y., Cheng, Q., Bosnjak, Z., Jiang, M.T., Cardiac mitochondrial ATP-sensitive potassium channel is activated by nitric oxide in vitro. FEBS Lett 581:22 (Sep 4 2007), 4255–4259.
57. Harada, N., Miura, T., Dairaku, Y., Kametani, R., Shibuya, M., Wang, R., et al. NO donor-activated PKC-delta plays a pivotal role in ischemic myocardial protection through accelerated opening of mitochondrial K-ATP channels. J Cardiovasc Pharmacol 44:1 (Jul 2004), 35–41.
58. Xu, Z., Ji, X., Boysen, P.G., Exogenous nitric oxide generates ROS and induces cardioprotection: involvement of PKG, mitochondrial KATP channels, and ERK. Am J Physiol Heart Circ Physiol 286:4 (Apr 2004), H1433–H1440.
59. Gross, E.R., Nithipatikom, K., Hsu, A.K., Peart, J.N., Falck, J.R., Campbell, W.B., et al. Cytochrome P450 omega-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal KATP channel. J Mol Cell Cardiol 37:6 (Dec 2004), 1245–1249.
60. Kim, J.H., Chun, K.J., Park, Y.H., Kim, J., Kim, J.S., Jang, Y.H., et al. Morphine-induced postconditioning modulates mitochondrial permeability transition pore opening via delta-1 opioid receptors activation in isolated rat hearts. Korean J Anesthesiol 61:1 (Jul 2011), 69–74.